Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.

Abstract:

BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and feasibility of S-1 monotherapy in elderly patients with NSCLC who had previously received other treatments. METHODS:We included 96 elderly patients (aged ≥75 years) with advanced NSCLC treated with S-1 alone as a subsequent-line treatment at 12 medical facilities between January 2005 and March 2018 in this study. The baseline characteristics of the patients, response to S-1 monotherapy, and adverse events (AEs) were investigated, retrospectively. RESULTS:A total of 68 male and 28 female patients (median age, 78 [range: 75-86] years) were analyzed. In elderly patients who were treated with S-1 monotherapy as a subsequent-line treatment, the objective response rate, disease control rate, median progression-free survival (PFS), and overall survival (OS) were 8.3%, 43.8%, 3.4 months, and 9.6 months, respectively. Observed AEs included anorexia, anemia, nausea, fatigue, reduced platelet count, and skin hyperpigmentation. Treatment-related death was observed in one patient because of pneumonitis. In patients who experienced no progressive disease, subsequent-line S-1 alone was associated with longer PFS and OS. CONCLUSIONS:S-1 monotherapy is effective and feasible as a subsequent-line treatment in elderly patients who were previously treated for NSCLC, and it produces results. S-1 monotherapy could be one of the treatment choices for elderly patients with previously treated NSCLC.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Imai H,Minemura H,Kishikawa T,Yamada Y,Suzuki K,Umeda Y,Wasamoto S,Kasahara N,Ishihara S,Yamaguchi O,Naruse I,Uchino J,Mori K,Kanazawa K,Shibata Y,Kasai T,Kaburagi T,Kaira K,Minato K

doi

10.1111/1759-7714.13622

subject

Has Abstract

pub_date

2020-10-01 00:00:00

pages

2867-2876

issue

10

eissn

1759-7706

issn

1759-7714

journal_volume

11

pub_type

杂志文章
  • Early-onset interstitial pneumonitis in a patient with advanced non-small cell lung cancer treated with crizotinib and osimertinib.

    abstract::Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13785

    authors: Cheng Y,Yu Q,Xiong Y,Guo C,Nie L

    更新日期:2021-01-12 00:00:00

  • Primary inflammatory myofibroblastic tumor of the diaphragm: Report of a case.

    abstract::We report a case of primary inflammatory myofibroblastic tumor of the diaphragm in a 64-year-old man. The patient was hospitalized for a computed tomography (CT)-detected large tissue mass at the left lower lung field. Complete tumor excision followed by pathological investigation was performed. Microscopically, the t...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2012.00155.x

    authors: Fu J,Wu Q,Zhang Y,Zhang X,Wang Z

    更新日期:2013-11-01 00:00:00

  • Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.

    abstract::Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12557

    authors: Okamura K,Fukuda Y,Soda H,Ogawara D,Iwasaki K,Fuchi S,Suyama T,Yoshida M,Harada T,Fukuda M,Mukae H

    更新日期:2018-01-01 00:00:00

  • Overexpression of micro ribonucleic acid-591 inhibits cell proliferation and invasion of malignant pleural mesothelioma cells.

    abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive cancer refractory to current therapies. Reduced expression of micro ribonucleic acid (miR)-591 in a range of cancer types has suggested it is a potent tumor suppressor, and overexpression has been shown to inhibit tumor cell growth. The role of miR-591 in...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12336

    authors: Cheng S,Xu Y,Shi Z,Lin Y,Hoang CD,Zhang X

    更新日期:2016-04-26 00:00:00

  • Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma.

    abstract::A 57-year-old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantl...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12506

    authors: Wang H

    更新日期:2017-11-01 00:00:00

  • Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab.

    abstract::Several authors have previously reported that patients with pulmonary combined large cell neuroendocrine cancer ( LCNEC) have a poor prognosis and there is no consensus on the treatment strategy for combined LCNEC as well as LCNEC. Here, we report the case of a long-term survivor with pulmonary combined LCNEC. The pat...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13471

    authors: Oda R,Okuda K,Yamashita Y,Sakane T,Tatematsu T,Yokota K,Endo K,Nakanishi R

    更新日期:2020-07-01 00:00:00

  • Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases.

    abstract::After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving therapy with tyrosine kinase inhibitors develop drug resistance through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in epidermal growth factor receptor-mutated and anaplastic lymphom...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12416

    authors: Mengoli MC,Orsi G,Lococo F,Grizzi G,Barbieri F,Bertolini F,Rossi G,Novello S

    更新日期:2017-07-01 00:00:00

  • Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).

    abstract::Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9-14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-f...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1759-7714.12923

    authors: Okuma Y,Morikawa K,Tanaka H,Yokoyama T,Itani H,Horiuchi K,Nakagawa H,Takahashi N,Bessho A,Soejima K,Kishi K,Togashi A,Kanai Y,Ueda K,Horimoto K,Matsutani N,Seki N

    更新日期:2019-02-01 00:00:00

  • Efficacy of repeated surgery is superior to that of non-surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer.

    abstract:BACKGROUND:The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS:All cases of lung cancer included in our prospective database between January 2000 and J...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12790

    authors: Zhou H,Kang X,Dai L,Yan W,Yang Y,Lin Y,Chen KN

    更新日期:2018-08-01 00:00:00

  • Risk factors for disseminated intravascular coagulation in patients with lung cancer.

    abstract:BACKGROUND:The mortality rate from disseminated intravascular coagulation (DIC) is higher in patients with lung cancer than in non-lung cancer patients. Moreover, the prevalence of DIC varies among the pathologic types of lung cancer. This study analyzed the relationship between coagulation factors and the pathologic t...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12766

    authors: Nakano K,Sugiyama K,Satoh H,Shiromori S,Sugitate K,Arifuku H,Yoshida N,Watanabe H,Tokita S,Wakayama T,Tatewaki M,Souma R,Koyama K,Hirata H,Fukushima Y

    更新日期:2018-08-01 00:00:00

  • Cloning short DNA into plasmids by one-step PCR.

    abstract:BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13660

    authors: Tao CC,Yang Y,Li F,Qiao L,Wu Y,Sun XD,Zhang YY,Li CL

    更新日期:2020-11-01 00:00:00

  • New relationship of E2F1 and BNIP3 with caveolin-1 in lung cancer-associated fibroblasts.

    abstract::In recent years, studies have found that E2F1, a downstream effector of caveolin-1 (Cav-1), participates in tumor cell metabolic reprogramming. E2F1 modulates mitochondrial fusion and mitophagy. Bioinformatic analysis has identified the E2F1-MFN2 axis as a regulator of mitophagy. Our data establish a new novel paradig...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13408

    authors: Shen C,Chen X,Xiao K,Che G

    更新日期:2020-06-01 00:00:00

  • Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.

    abstract:BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13241

    authors: Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

    更新日期:2020-01-01 00:00:00

  • Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer.

    abstract:BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12232

    authors: Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

    更新日期:2015-09-01 00:00:00

  • LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non-small cell lung cancer cells via the miR-361-3p/FRAT1 axis.

    abstract:BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13256

    authors: Li X,Zheng H

    更新日期:2020-02-01 00:00:00

  • P16INK4a gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis.

    abstract:BACKGROUND:This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS:Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chine...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,meta分析

    doi:10.1111/1759-7714.12783

    authors: Tuo L,Sha S,Huayu Z,Du K

    更新日期:2018-08-01 00:00:00

  • Lung adenocarcinoma with anomalous bronchi and pulmonary veins preoperatively identified by computed tomography.

    abstract::A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12362

    authors: Tajima K,Uchida N,Sasamoto H,Okada T,Kohri T,Mogi A,Kuwano H

    更新日期:2016-09-01 00:00:00

  • A nurse-driven enhanced recovery after surgery (ERAS) nursing program for geriatric patients following lung surgery.

    abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13372

    authors: Li Y,Yan C,Li J,Wang Q,Zhang J,Qiang W,Qi D

    更新日期:2020-04-01 00:00:00

  • Impact of target area selection in 125 Iodine seed brachytherapy on locoregional recurrence in patients with non-small cell lung cancer.

    abstract:BACKGROUND:Computed tomography (CT)-guided percutaneous implantation of 125 Iodine radioactive seeds requires the precise arrangement of seeds by tumor shape. We tested whether selecting target areas, including subclinical areas around tumors, can influence locoregional recurrence in patients with non-small cell lung c...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12415

    authors: Yan WL,Lv JS,Guan ZY,Wang LY,Yang JK,Liang JX

    更新日期:2017-05-01 00:00:00

  • Comparative study of esophagectomy, endoscopic therapy, and radiotherapy for cT1N0M0 esophageal cancer in elderly patients: A SEER database analysis.

    abstract:BACKGROUND:The number of patients diagnosed with early stage disease (T1a or T1b) has been increasing. This study was conducted to investigate the effect of esophagectomy (ES), endoscopic therapy (ET), and radiotherapy (RT) on long-term survival in elderly patients with cT1N0M0 esophageal cancer. METHODS:We searched t...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13080

    authors: Qin J,Peng Y,Chen W,Ma H,Zheng Y,Li Y,Wang J

    更新日期:2019-07-01 00:00:00

  • Complete remission and fatal interstitial pneumonitis related to nab-paclitaxel in refractory small cell lung cancer: A case report and review of the literature.

    abstract::For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2011.00086.x

    authors: Wang B,Yang J,Luo D,Qiao H,Xie Z,Zhang X,Wu Y

    更新日期:2012-02-01 00:00:00

  • Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports.

    abstract:BACKGROUND:Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the effective medicines in advanced lung adenocarcinoma leptomeningeal metastasis (LM) treatment in recent years. METHODS:This paper reports two cases of advanced lung adenocarcinoma with exon-EGFR19 mutation. LM occurred during gefit...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12049

    authors: Xing P,Li J,Shi Y,Zhang X

    更新日期:2014-01-01 00:00:00

  • Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.

    abstract:BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13360

    authors: Mizuno T,Horinouchi H,Watanabe S,Sato J,Morita R,Murakami S,Goto Y,Kanda S,Fujiwara Y,Yamamoto N,Ohe Y

    更新日期:2020-04-01 00:00:00

  • Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.

    abstract:BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13226

    authors: Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

    更新日期:2019-12-01 00:00:00

  • Three-dimensional (3D)-printed titanium sternum replacement: A case report.

    abstract::After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three-dimensional (3D)-printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stabilit...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13655

    authors: Wang W,Liang Z,Yang S,Feng Q,Nie X,Su G,Yuan W,Han Y

    更新日期:2020-11-01 00:00:00

  • Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis.

    abstract:BACKGROUND:The impact of adjuvant treatment for esophageal carcinoma with tumor-negative lymph nodes after upfront radical esophagectomy is still uncertain. This study investigated the effects of postoperative radiotherapy in pT1-3N0 esophageal carcinoma after radical resection. METHOD:We retrospectively identified pT...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13235

    authors: Gao HJ,Shang XB,Gong L,Zhang HD,Ren P,Shi GD,Wei YC,Yu ZT

    更新日期:2020-02-01 00:00:00

  • Metastasis in the subcarinal lymph node with unknown primary tumor.

    abstract::A 59-year-old man with previous anaplastic large cell T-cell lymphoma stage 3A was admitted with an isolated positron emission tomography(PET)-positive spot in a subcarinal lymph node. Diagnosis was achieved with endobronchial ultrasound-guided fine-needle aspiration demonstrating a well-differentiated squamous cell c...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2010.00039.x

    authors: Eckardt J,Olsen KE,Petersen H

    更新日期:2011-05-01 00:00:00

  • Efficacy of radiofrequency ablation and microwave ablation in the treatment of thoracic cancer: A systematic review and meta-analysis.

    abstract:BACKGROUND:Radiofrequency ablation and microwave ablation are frequently prescribed for thoracic cancer. However, few writers have been able to draw on any systematic research into the differences between the two ablation methods. METHODS:A literature search was carried out using Embase, PUBMED, Web of Science, Cochra...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1759-7714.12973

    authors: Sun YD,Zhang H,Liu JZ,Xu HR,Wu HY,Zhai HZ,Lu CY,Zhao X,Chen YQ,Zhou LL,Han JJ

    更新日期:2019-03-01 00:00:00

  • Metastatic meningeal carcinomatosis from lung cancer: Report of a rare case.

    abstract::Meningeal carcinomatosis (MC) refers to the diffuse or multifocal spread or infiltration of malignant tumors in the pia mater. It is a special distribution type of metastatic tumors in the central nervous system and one of the important reasons of death caused by metastatic malignant tumors. Here, we report a rare cas...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13243

    authors: Liu H,Liu L,Zhang X,Jin S

    更新日期:2020-01-01 00:00:00

  • Bronchoscopic debulking for endobronchial malignancy: Predictors of recanalization and recurrence.

    abstract:BACKGROUND:Central airway obstruction related to endobronchial malignancy is one of the most difficult oncological complications and requires efficient palliative intervention. METHODS:Fifty-three consecutive patients with unresectable endobronchial malignancy receiving bronchoscopic cryotherapy as palliative treatmen...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12248

    authors: Kuo SC,Lo YL,Chou CL,Chung FT,Lin SM,Liu CY,Kuo HP

    更新日期:2015-11-01 00:00:00